Andexanet alfa (Ondexxya)
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- December 2019
Comments
RED:
- NICE TA697: Andexanet alfa for reversing anti-coagulation from apixaban or rivaroxaban. (Decision date - June 2021)
DO NOT PRESCRIBE (DNP):
- NICE TA697: for research for reversing
anti-coagulation from apixaban or rivaroxaban in adults with life-threatening or
uncontrolled bleeding in the skull (intracranial haemorrhage), in the form
of an ongoing randomised trial mandated by the regulator. (Decision date - June 2021)
Red Drug Classifications
- 4: Specifically designated as “hospital only” by product licence or by DH/NICE
search again